Pediatric idiopathic TTP diagnosed with decreased ADAMTS13 activity

Pediatrics International

Volumn 54, Issue 3, 2012, Pages 422-423

  Morishima, Tatsuya ^a   Nomura, Anryu ^a   Saida, Satoshi ^a   Watanabe, Ken Ichiro ^a   Yagi, Hideo ^c   Matsumoto, Masanori ^c   Fujimura, Yoshihiro ^c   Heike, Toshio ^a   Nakahata, Tatsutoshi ^a,b   Adachi, Souichi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

ADAMTS13; ADAMTS13 inhibitor; idiopathic thrombotic thrombocytopenic purpura; plasma exchange

Indexed keywords

ANTINUCLEAR ANTIBODY; BILIRUBIN; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PREDNISOLONE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BILIRUBIN BLOOD LEVEL; BLOOD SMEAR; CASE REPORT; CHILD; ECCHYMOSIS; ENZYME ACTIVITY; FEMALE; FEVER; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DISCHARGE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; JAUNDICE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA; LEUKOCYTE COUNT; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; SCHOOL CHILD; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

ADAM PROTEINS; CHILD; FEMALE; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84861643914     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2011.03467.x     Document Type: Article

References (10)

1. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B,. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
2. Furlan M, Robles R, Galbusera M, et al,. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N. Engl. J. Med. 1998; 339: 1578-84.
3. Tsai HM, Lian EC,. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 1998; 339: 1585-94.
4. Levy GG, Nichols WC, Lian EC, et al,. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
5. Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL,. Thrombotic thrombocytopenic purpura in childhood. Pediatr. Blood Cancer 2009; 53: 537-42.
6. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN,. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: All patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J. Thromb. Haemost. 2005; 3: 1432-6.
7. Rock GA, Shumak KH, Buskard NA, et al,. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N. Engl. J. Med. 1991; 325: 393-7.
8. Loirat C, Girma JP, Desconclois C, Coppo P, Veyradier A,. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr. Nephrol. 2009; 24: 19-29.
9. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP,. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 2001; 98: 1765-72.
10. Peyvandi F, Lavoretano S, Palla R, et al,. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232-9.